These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26023149)

  • 21. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2.
    Wang J; Ma C; Fiorin G; Carnevale V; Wang T; Hu F; Lamb RA; Pinto LH; Hong M; Klein ML; DeGrado WF
    J Am Chem Soc; 2011 Aug; 133(32):12834-41. PubMed ID: 21744829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of anti-influenza drug].
    Zhang T; Wang CY; Gao YW; Yang ST; Wang TC; Xia XZ
    Bing Du Xue Bao; 2011 Sep; 27(5):475-80. PubMed ID: 21998961
    [No Abstract]   [Full Text] [Related]  

  • 23. Emerging Roles of Viroporins Encoded by DNA Viruses: Novel Targets for Antivirals?
    Royle J; Dobson SJ; Müller M; Macdonald A
    Viruses; 2015 Oct; 7(10):5375-87. PubMed ID: 26501313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.
    Wang J; Li F; Ma C
    Biopolymers; 2015 Jul; 104(4):291-309. PubMed ID: 25663018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy.
    Shaw J; Gosain R; Kalita MM; Foster TL; Kankanala J; Mahato DR; Abas S; King BJ; Scott C; Brown E; Bentham MJ; Wetherill L; Bloy A; Samson A; Harris M; Mankouri J; Rowlands DJ; Macdonald A; Tarr AW; Fischer WB; Foster R; Griffin S
    Elife; 2020 Nov; 9():. PubMed ID: 33169665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the Channel Activity of Viroporins.
    To J; Surya W; Torres J
    Adv Protein Chem Struct Biol; 2016; 104():307-355. PubMed ID: 27038378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing antiviral therapy for influenza: understanding the evidence.
    Ison MG
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the function and inhibition of an influenza virus proton channel.
    Stouffer AL; Acharya R; Salom D; Levine AS; Di Costanzo L; Soto CS; Tereshko V; Nanda V; Stayrook S; DeGrado WF
    Nature; 2008 Jan; 451(7178):596-9. PubMed ID: 18235504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Situ Spectroscopic Detection of Large-Scale Reorientations of Transmembrane Helices During Influenza A M2 Channel Opening.
    Paschke RR; Mohr S; Lange S; Lange A; Kozuch J
    Angew Chem Int Ed Engl; 2023 Nov; 62(47):e202309069. PubMed ID: 37733579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.
    Balannik V; Wang J; Ohigashi Y; Jing X; Magavern E; Lamb RA; Degrado WF; Pinto LH
    Biochemistry; 2009 Dec; 48(50):11872-82. PubMed ID: 19905033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses.
    Ma C; Wang J
    Biochim Biophys Acta Biomembr; 2018 Feb; 1860(2):272-280. PubMed ID: 29106970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viroporins.
    Gonzalez ME; Carrasco L
    FEBS Lett; 2003 Sep; 552(1):28-34. PubMed ID: 12972148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus.
    Huang RB; Du QS; Wang CH; Chou KC
    Biochem Biophys Res Commun; 2008 Dec; 377(4):1243-7. PubMed ID: 18996090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.
    Jalily PH; Eldstrom J; Miller SC; Kwan DC; Tai SS; Chou D; Niikura M; Tietjen I; Fedida D
    Mol Pharmacol; 2016 Aug; 90(2):80-95. PubMed ID: 27193582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An assay suitable for high throughput screening of anti-influenza drugs.
    Mao L; Wang J; DeGrado WF; Inouye M
    PLoS One; 2013; 8(1):e54070. PubMed ID: 23326573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.
    Musharrafieh R; Lagarias PI; Ma C; Tan GS; Kolocouris A; Wang J
    Mol Pharmacol; 2019 Aug; 96(2):148-157. PubMed ID: 31175183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza virus nucleoprotein: structure, RNA binding, oligomerization and antiviral drug target.
    Chenavas S; Crépin T; Delmas B; Ruigrok RW; Slama-Schwok A
    Future Microbiol; 2013 Dec; 8(12):1537-45. PubMed ID: 24266354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of drug inhibition and drug resistance of influenza A M2 channel.
    Pielak RM; Schnell JR; Chou JJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7379-84. PubMed ID: 19383794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiscale Simulation of an Influenza A M2 Channel Mutant Reveals Key Features of Its Markedly Different Proton Transport Behavior.
    Watkins LC; DeGrado WF; Voth GA
    J Am Chem Soc; 2022 Jan; 144(2):769-776. PubMed ID: 34985907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein structural defects enable pharmaceutical targeting while functionalizing the M2 proton channel.
    Fernández A
    Biochem Biophys Res Commun; 2019 Jun; 514(1):86-91. PubMed ID: 31023526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.